Digital Therapeutics Startup Fitterfly Raises $3.1 Mn From Fireside Ventures


Healthtech startup Fitterfly raised $3.1mn led by Fireside Ventures, where 9Unicorns and Venture Catalysts and a clutch of angel investors also participated.


Fitterfly offers personalised digital therapeutics (DTx) programmes for diabetes, pregnancy, polycystic ovary syndrome and obesity to deliver health outcomes. Its 140-plus member team comprises senior doctors, nutritionists, psychologists, fitness experts, management experts and technologists.


Designed to complement doctors’ medical therapy, Fitterfly’s DTx programmes offer 360-degree guidance around nutrition, exercise, sleep, stress and other factors which affect health outcomes. More than 10,000 people have subscribed so far, said CEO Singal.


The Fitterfly team started building a clinical nutrition database four years ago and then validated it by building disease-specific nutrition advisory algorithms. It launched DTx in late 2019, recognising the large unmet need for remote support in improving outcomes.


“Covid-19 has pushed remote monitoring and digital therapeutics to the forefront of medicine,” said Singal. “We are solving difficult problems—be it diabetes, obesity, women’s health or child health, through our innovative digital therapeutics solutions. These problems affect almost 30-40% of the population in India. We are seeing good support from doctors as a prescription product, saving their time and helping them achieve better outcomes.”


“In the current post-pandemic era, we at Fireside believe that brands, platforms and enterprises that address and serve well-being, holistic living and health needs and concerns of consumers, have acquired greater acceptance,” said Kanwaljit Singh, managing partner at Fireside Ventures, who will now join Fitterfly as a board member. “Consumers are now amenable and willing to consider and adopt digital solutions that promise to improve and enhance their quality of life and keep them in a state of good health. The segment of digital therapeutics represents an incredible growth opportunity for us.”

442 views0 comments